* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Pilocarpine as a Treatment for Open Angle Glaucoma
Blast-related ocular trauma wikipedia , lookup
Keratoconus wikipedia , lookup
Visual impairment wikipedia , lookup
Idiopathic intracranial hypertension wikipedia , lookup
Eyeglass prescription wikipedia , lookup
Corneal transplantation wikipedia , lookup
Visual impairment due to intracranial pressure wikipedia , lookup
Dry eye syndrome wikipedia , lookup
It is estimated 2 out of every 100 people over the age of 65 have glaucoma and half of these people don’t know it. From Cassel, Billig, Randall Pilocarpine as a Treatment for Open Angle Glaucoma By Tom Zurakowski Objective: Inform my audience about glaucoma and the use of pilocarpine as a treatment for open angle glaucoma. The Eye Major Parts of the Eye Ciliary body Cornea Iris Pupil Sclera Choroid Retina Optic Nerve Anterior Segment Lens Canal of Schlemm Posterior Segment (contains vitreous humor) Marieb Fig16-6 Eye Fluid Production and Pressure Cornea Iris Anterior chamber angle Trabecular meshwork Schlemm’s canal (out) Pupil Posterior chamber Ciliary body (in) Lens Vitreous Zonule Cassel, Billig, Randall Fig 8-2 Intraocular Pressure (IOP) • Eye is like a balloon • “Normal Pressure” (16 - 21)mm Hg • Continuous replacement of aqueous humor • Measurement of Pressure (tonometry) 1) Goldmann contact tonometer 2) “air puff” tonometer Glaucoma - What is it? - Types of Glaucoma 1) Closed-Angle Glaucoma 2) Open-Angle Glaucoma 3) Normotensive (Low Tension) Glaucoma - Who’s at risk 1) > age 55 2) family history 3) having diabetes 4) being very nearsighted 5) African American - Effects of Glaucoma 1) Tunnel Vision 2) Blindness Types of Glaucoma Open-Angle Glaucoma Blocked drainage of aqueous Blocked drainage of aqueous Anterior chamber open Blockage at trabecular meshwork Cassel, Billig, Randall Closed-Angle Glaucoma Fig 8-4 Anterior Chamber angle closure Cassel, Billig, Randall Fig 8-3 Effect of Glaucoma Cause of Blindness - Cupping of Optic Nerve Cassel, Billig, Randall Pilocarpine -Origin of the Drug -South American Shrub - Pilocarpus jaborandi -Isolated in 1875 -Chemical Structure + - Cholinergic Parasympathomimetic agent Reaction Mechanism - Pilocarpine binds to muscarinic receptor - Activates receptor binds G-protein - Removal of GDP and addition of GTP to G-protein - Dissociation of G-protein from muscarinic receptor - Separation of G-protein into alpha and beta-gamma subunits - Alpha subunit interacts with and activates Phospholipase C Phosphatidyl inositol biphosphate (PIP) complex - Phospholipase breaks down PIP into inositol 1,4,5-triphosphate (IP3)and diacylglycerol (both 2o) - IP3 interacts with ER membrane which releases Ca2+ Muscle Action - Ca2+ binds to calmodulin forming a complex - This complex binds to caldesmon - When caldesmon is bound by Ca2+/calmodulin complex this allows myosin-actin interactions to occur -The muscle (pupil)contracts Marieb Fig 16-7 Reaction Sequence Phospholipase C Phosphatidyl inositol biphosphate (PIP) complex G- Protein subunits , , GDP\ Inositol 1,4,5 - triphosphate (IP3) + diacylglycerol GTP Myosin-actin interactio (Muscle Contraction) Muscarinic Receptor caldesmon Endoplasmic Reticulum Ca2+ Calmodulin/ Ca2 The End Result - Contraction of pupil and stimulation of ciliary muscle - Tension on scleral spur opening trabecular meshwork - Increased out flow, lowering of pressure Bibliography 1. Cassel, Gary, H., Michael D.Billig, and Harry G.Randall The Eye Book. The Johns Hopkins University Press. Baltimore, Maryland. 1998. 2. Finn, Paul, Registered Pharmacist Luther Hospital, Eau Claire, WI. Personal Interview. 17 Feb. 1999. 3. Nybakken, Craig, Registered Pharmacist Luther Hospital, Eau Claire, WI Pesonal Interview. 17 Feb. 1999. 4. Hardman, Joel, G., Lee E. Limbird, (et.al.) Goodman's and Gilman's Pharmacological Basis of Therapeutics. 9th ed. R.R. Donnelly and Sons Co. New York, NY. 1996. 5. Riley, Michael, R., Steven, K Hebel, (et.al) Drug Facts and Comparisons. Wolters Kluwer Co. St. Louis, MO 1999. 6. MBC 3320: Lecture 3 (January 19,1999) [Online] Available World Wide Web http://www.neurosci.pharm.utoledo.edu/MBC3320/lecture03.html 7. Allen, James, H. May's Diseases of the Eye. Robert E. Krieger Publishing Co. Huntington, NY. 1976. 8. Occular Pharmacology [Onlilne] Available World Wide Web http://www.eye.ttu.edu/lectures/Crosson_OcPharm.html 9. Cholinergic receptors [Online] Available World Wide Web http://www.kumc.edu/research/medicine/pharmacology/mgordon/Autonomics/Introduction/enrich3.htm. 10. ANS neurotransmitters [Online] Available World Wide Web http://www.kumc.edu/research/medicine/pharmacology/mgordon/Autonomics/Cholinergics/ans_trans1.htm#Eye 11. Marieb, Elaine, N. Human Anatomy & Physiology. 4th ed. Addison Wesley Longman, Inc. Menlo Park, CA. 1998. 12. Randall, David, Warren Burggren, Kathleen French. Animal Physiology Mechanisms and Adaptations. 4th ed. W.H. Freeman and Co. New York, NY 1997. 13. Stryer, Lubert. Biochemistry. 2nd Ed. W.H. Freeman and Co. SanFransico, CA 1981. 14. Waschke, Kevin A. (1996) New Perspectivies in the Pharmacologic Treatment of Primary Open-Angle Glaucoma: Pathogenesis and Patient Factors. [Online] Available World Wide Web: http://www.mjm.mcgill.ca/back_issues/V2n1/glaucoma.html